We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Smith & Nephew Plc | SN. | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -12.80 | -1.30% | 970.60 | 15:06:48 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 982.60 | 969.80 | 987.40 | 983.40 |
| Industry Sector |
|---|
| HEALTH CARE EQUIPMENT & SERVICES |
| Announcement Date | Type | Currency | Dividend Amount | Ex Date | Record Date | Payment Date |
|---|---|---|---|---|---|---|
| 27/02/2024 | Final | USD | 0.231 | 28/03/2024 | 02/04/2024 | 22/05/2024 |
| 03/08/2023 | Interim | USD | 0.144 | 05/10/2023 | 06/10/2023 | 01/11/2023 |
| 21/02/2023 | Final | USD | 0.231 | 30/03/2023 | 31/03/2023 | 17/05/2023 |
| 28/07/2022 | Interim | USD | 0.144 | 29/09/2022 | 30/09/2022 | 26/10/2022 |
| 22/02/2022 | Final | USD | 0.231 | 31/03/2022 | 01/04/2022 | 11/05/2022 |
| Top Posts |
|---|
Posted at 06/3/2024 13:38 by cerrito Interested to read this in Citywirequote he market has an ‘unconscious bias’ against Smith & Nephew (SN) and always assumes the worst about the medical technology company, says Liberum. Analyst Seb Jantet retained his ‘buy’ recommendation and target price of £12.85 on the Citywire Elite Companies AA-rated provider of hip and knee implants, which rose 0.3% to £10.46 on Tuesday. ‘We are slightly perplexed by the market’s reaction to Smith & Nephew’s full-year results,’ Jantet said. ‘Trading was in line and there was a solid guide for full year 2024. And while the initial share price reaction was positive, the shares fell sharply over the next few days. ‘Understandabl He added that ‘both the revenue and margin guides are achievable’ and said the ‘discount to peers is too high’. |
Posted at 13/10/2023 12:43 by essentialinvestor Might be worth looking at what the CEO does.. ?His large sales at £12.74 and £12.78 now look very astute. 5 different CEO's in 10 years, eh A rating of 16 X forward looks more than fair for SN. in a post ZIRP world. The market might see it differently, but that's how it looks to me. |
Posted at 12/10/2023 14:58 by essentialinvestor Laurence, part of the issue is arguably their main competitors growing strongerv SN over the last decade. This may account for some of SN's weaker metrics. While a bid can't be ruled out, it has been mentioned as a takeover candidate for decades. If you go back 10 years, this was a high margin business with low gearing and a prodigious cash generator. Those bullish on SN may say that's now reflected in the current share price, however circa 2013, at approx £8 plus a share you were buying at the time a great business. |
Posted at 12/10/2023 09:01 by essentialinvestor How are margins stable?, trading profit margin registered a hefty fall at the H1 to15.3%. For years SN had trading profit margins in excess of 20%, for a few years around 24/25%. Margins began a multi year decline around 2015/16 (from memory) and despite multiple CEO's since, each with a new refreshed strategy to improve business performance, results have arguably been sadly lacking. Margin compression leading to reduced free cash flow is central to the bearish case on SN. |
Posted at 11/10/2023 15:15 by essentialinvestor Stryker do not need SN, while you can't rule a bid out I would be surprised to see one from Stryker. |
Posted at 05/10/2023 08:27 by pugugly Ex Dividend today - 11.915p |
Posted at 21/2/2023 08:42 by adamb1978 Nothing exciting no, but equally still nothing to suggest that they're ever going to deliver decent ROE, ROCE etcAlways felt to me that SN achieves a fraction of its potential. Why...I'm not sure |
Posted at 07/12/2022 15:38 by suetballs Glad this wasn't sn.Suet |
Posted at 04/11/2022 17:32 by cerrito As a SN. holder I listened to most of the recording of yesterday's webcast.Alot of good stuff especially in logistics and optimization of inventory and US improvement but what stopped me pushing the buy button was not so much the supply shortages(especially semi conductors and resins) but rather that in the Q&A the difficulty they were having on passing on cost increases came up 2/3 times. |
Posted at 03/11/2022 10:19 by disc0dave45 Seem to be following the same stocks!From the healthcare sector I've got SN on my watchlist and good to see they are in line. Some of the constraining factors (materials and staff shortages, FX headwinds) could develop into major issues but who knows. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
